MBX Biosciences, Inc. Email Format
Biotechnology ResearchIndiana, United States51-200 Employees
MBX Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision peptide therapies for endocrine and metabolic disorders. Its Precision Endocrine Peptides (PEPs) are designed to overcome limitations of native peptide drugs to deliver improved pharmacologic properties. The company maintains a pipeline of PEP candidates aimed at unmet needs in endocrine disease, led by MBX 2109 for hypoparathyroidism, which is in a Phase 1 trial. Based in Carmel, Indiana, MBX positions itself within the biotechnology research space, pursuing early development of novel peptide therapeutics. In 2026 the company expanded its leadership with the appointment of Mark R. Soued as Chief Commercial Officer. MBX participates in industry events and investor conferences to share updates on its programs, including appearances at ENDO 2026.